Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 113Lymphoma, Mantle-Cell 65Lymphoma, Large B-Cell, Diffuse 40Lymphoma, Non-Hodgkin 31Lymphoma, Follicular 30Waldenstrom Macroglobulinemia 29Lymphoma 29Lymphoma, B-Cell 22Recurrence 21Lymphoma, B-Cell, Marginal Zone 19Neoplasms 16Leukemia 14Leukemia, B-Cell 10Multiple Myeloma 9Bronchiolitis Obliterans Syndrome 9Leukemia, Lymphoid 8Burkitt Lymphoma 8Hematologic Neoplasms 7Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Hodgkin Disease 5Leukemia, Prolymphocytic 4Graft vs Host Disease 4Lymphoproliferative Disorders 3Lymphatic Diseases 3Leukemia, Hairy Cell 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Diseases 3Chromosome 17 deletion 3

Interventions

Everolimus 10Octreotide 7pasireotide 5lanreotide 5gallium Ga 68 dotatate 4lutetium Lu 177 dotatate 3cabozantinib 3Sunitinib 3Nivolumab 3ganitumab 2Temozolomide 2Erlotinib Hydrochloride 2Capecitabine 2Bevacizumab 2zimberelimab 1veliparib 1telotristat ethyl 1surufatinib 1recombinant interferon alpha 2b-like protein 1pertuzumab 1pembrolizumab 1olaparib 1nintedanib 1ibrutinib 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1carfilzomib 1azaspirane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoid Tumor × ibrutinib × Clear all
NCT02575300 2020-09-11

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
20 enrolled 11 charts
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡